Extracorporeal membrane oxygenation (ECMO) uses technology derived from cardiopulmonary bypass (CPB) that allows gas exchange outside the body. In addition, circulatory support can also be provided. ECMO has been used for more than 40 yr and its benefits in neonates with respiratory distress, when provided in specialized centres, are well recognized. The benefits of ECMO in adult patients with cardiac failure or refractory acute respiratory distress syndrome (ARDS) are still debated, as ECMO was initially associated with poor survival rates. 1 However, recent technological advances in the ECMO circuit have led to a reduction in the rate of technical issues and complications. Moreover, improved understanding of the benefits of ECMO has emerged from its widespread use as a rescue therapy for patients with ARDS and refractory hypoxaemia associated with H1N1/ 2009 infection ('swine flu'). The aim of this article is to describe briefly the ECMO circuit, overview the physiological implications of its use, and discuss the evidence supporting the application of ECMO in adult patients.
Types of ECMO and indications

ECMO circuit
An ECMO circuit can be set up in three ways:
(i) veno-arterial ECMO (VA-ECMO): allows gas exchange and haemodynamic support while blood is pumped from the venous to the arterial side; (ii) veno-venous (VV-ECMO): facilitates gas exchange; blood is removed from the venous side and then pumped back into it, but does not provide haemodynamic support; (iii) arterio-venous ECMO (AV-ECMO): facilitates gas exchange by using the patient's own arterial pressure to pump the blood from the arterial to the venous side.
The circuit setup for VA or VV is almost identical. Blood movement is facilitated by an external pump that then pushes the blood through a membrane allowing gas exchange (oxygenation and CO 2 removal), before returning the blood to the patient's circulation via a warmer. Due to its configuration, VA-ECMO bypasses the patient's heart and lung and part or all of the blood flow is diverted through the ECMO circuit. In contrast, VV-ECMO returns the blood before it enters the pulmonary circulation. When a pumpless circuit is used (AV-ECMO), blood flows from the femoral artery through a membrane and is passively returned into the femoral vein, the whole process dependent on the patient's cardiac output.
Indwelling cannulae, either venous or arterial, can be placed under direct vision (surgical cut-down) or via a percutaneous approach, ideally guided by ultrasound or fluoroscopy. The size and length of the cannula vary depending on the patient surface area, insertion site, type of circuit, and intended use. Centrifugal pumps are used as they are reliable and easy to care for.
The gas exchanger (oxygenator) allows more efficient CO 2 removal than O 2 addition because of the solubility and better diffusion properties of CO 2 relative to O 2 . The most recent models (hollow fibre non-micropore membrane) present less resistance to blood flow and are less traumatic to blood components than previous designs. They are also less thrombogenic; therefore, less anticoagulation is required.
Veno-arterial ECMO
In VA-ECMO, the drainage cannula is commonly placed in the inferior vena cava (IVC) or right atrium (RA). This can be done either
Key points
Extracorporeal membrane oxygenation (ECMO) is the use of a modified heart -lung machine to provide respiratory, circulatory, or both support at the bedside, usually for at least a number of days or even weeks.
ECMO is a valuable option for the management of severe but reversible causes of respiratory failure or cardiogenic shock refractory to conventional treatment.
Veno-venous ECMO is designed to provide gas exchange, while veno-arterial ECMO provides both gas exchange and haemodynamic support.
Acute respiratory distress syndrome associated with pneumonia (viral or bacterial) is the most common cause of refractory hypoxaemia that requires ECMO support.
A multidisciplinary approach and an effective referral network are essential. via a sternotomy or percutaneously by inserting the cannula via the internal jugular or the femoral vein. Blood is returned to the patient through a cannula inserted in either the ascending aorta (central ECMO, inserted surgically; Fig. 1A ) or the femoral artery ( peripheral ECMO, either surgically or percutaneously inserted; Fig. 1B ). Central ECMO is a preferred option when used immediately after CPB as the location of the cannulae is similar to the one used during surgery.
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VA-ECMO support decreases cardiac work and reduces cardiac oxygen consumption while providing adequate systemic organ perfusion with oxygenated blood. If cardiac recovery is expected, it is important that distension of the ventricles is reduced; VA-ECMO can achieve this if the left ventricle continues to eject or a vent (drainage catheter) is inserted directly into the left ventricle.
The diameter, length, and position of the cannulae used for vascular access determine potential flow that can be achieved. In addition, venous filling or patient preload, systemic vascular resistance or patient afterload, tubing resistance to flow, and pump properties are important factors.
VA-ECMO operates alongside the native system, and a proportion of the blood flow can continue to go through the lungs. Therefore, in a patient with impaired gas exchange, the proportion of blood going through the lungs will mix with well-oxygenated blood provided by the ECMO circuit in the aorta. The final content of oxygen depends on the combination of ECMO and patient's blood flows. This means that when using peripheral VA-ECMO, the neck vessels or coronaries may receive relatively poor oxygenated blood while the lower body receives better oxygenated blood.
Veno-venous ECMO
When the cardiac function is preserved, VV-ECMO is used to improve gas exchange. Traditionally, VV-ECMO required the insertion of at least two cannulae in large veins ( jugular, femoral, or both), sometimes more to facilitate drainage and flow and therefore oxygenation. A recently introduced dual-chamber cannula (Avalon Laboratories, Rancho Dominguez, CA, USA) allows efficient drainage from the inferior and superior vena cava and return of the blood through the RA into the tricuspid valve (Fig. 1C) . This new cannula decreases the incidence of recirculation (when oxygenated blood injected by the return cannula is drained immediately back to the ECMO by the drainage cannula), bleeding issues, and allows for greater patient mobilization. 2 
AV pumpless assist device
This system is characterized by a membrane gas exchange device integrated into a pumpless AV circuit, established by cannulation of the femoral artery and vein. The circuit allows a small amount Extracorporeal membrane oxygenation in adults of oxygenation but predominantly CO 2 removal, as arterial blood is returned to the venous side. AV-ECMO requires the patient to have a cardiac index of at least 2.5 litre min 21 m 22 that must be confirmed with echocardiography, invasive monitoring before insertion, or both.
ECMO indications
VA-ECMO is indicated in patients with refractory cardiogenic shock who have an underlying potentially reversible heart condition, although it can also be used as a bridge to a ventricular assist device or cardiac transplantation. VA-ECMO can also be used as a salvage technique during cardiac arrest, and the current data support its use after 10 min of adequate but unsuccessful Advanced Life Support (ALS). In-hospital survival rate of patients with VA-ECMO varies from 30% to 50% according to the cause of the cardiac dysfunction. 4 VA-ECMO can be considered in patients with systolic arterial pressure lower than 85 mm Hg, cardiac index lower than 1.2 litre min 21 m 22 , despite adequate preload, more than two inotropes in use, intra-aortic balloon counterpulsation, and systemic signs of low cardiac output. The paucity of data in the literature makes it difficult to determine which patients will benefit from VA-ECMO and when ECMO support will be futile. Thus, it is strongly recommended to discuss all possible cases with the nearest ECMO centre in these circumstances ( Table 1) . The aim of VV-ECMO in adult patients is to provide oxygenation and rest the lungs, decreasing the insult caused by mechanical ventilation. Hence, VV-ECMO should be considered as an alternative to conventional therapy for adults with ARDS and patients with graft dysfunction after lung transplantation 5 (Fig. 2) .
VV-ECMO has a lower risk of thromboembolic complications and lung perfusion allows endocrine pulmonary function in comparison with VA-ECMO. It is sometimes necessary to use VA-ECMO if significant haemodynamic compromise becomes apparent or if oxygenation that is provided is not sufficient; this may require changes of the cannulae position. ECMO is associated with significant inherent risks, and benefit compared with conventional therapies is still unclear. ECMO gained popularity during the H1N1/2009 pandemic, when clinicians were confronted with severe, refractory, and rapidly progressive hypoxaemia in young and fit patients. It made clinical sense to use the new generation of safer ECMO circuits in this situation. This was substantiated by the release of the Cesar trial results and no doubt catalysed by the media, influencing political choices. 6, 7 The Cesar trial is the third randomized controlled trial evaluating the benefits of ECMO in ARDS. The endpoint of the trial was to compare the survival at 6 months in the absence of severe disability, in patients who had developed ARDS and been randomized to be treated either in their original centre or in the treatment centre. The trial demonstrated that patients transferred to a centre with ECMO available had a better outcome than those treated at the original hospital with conventional therapy, and that this approach was cost-effective. Whether ECMO can really replace conventional treatment of adult ARDS is still unknown. Studies to determine the group that may benefit most are still lacking but patients mechanically ventilated for longer than 7 days or in multiorgan failure are considered poor candidates as underlying lung damage might then be irreversible, and ECMO is generally not offered. 8 ECMO therapy in ARDS allows a decrease in the stress imposed on the lung by ventilation at high airway pressure that may eventually damage the lung, and should be offered to patients with refractory hypoxaemia or hypercapnia despite optimal ventilation ( Table 1) . The best survival rates are observed in patients with nonnecrotizing viral pneumonia and associated respiratory failure, probably because (i) these are often younger patients, (ii) they have fewer co-morbidities, and (iii) the associated lung injury is often reversible.
AV-ECMO is particularly useful in patients with severe hypercapnia, respiratory acidosis, and moderate hypoxaemia. The absence of a pump makes this device simpler to use, but it means that cardiac function must be preserved for the blood to be effectively pumped. However, mortality has been reported to be high in patients with ARDS who had AV-ECMO, and some patients may require conversion from AV-ECMO to VV-or even VA-ECMO. 9 It does allow however easier transportation than other ECMO modes as no source of energy is required and it is smaller in size and weight.
ECMO management
Haemodynamic management can be particularly challenging. Initially, most patients require intravascular volume expansion. However, the institution of ECMO can lead to a rapid reduction in the doses of inotropic and vasoconstrictor drugs, as gas exchange improves and intrathoracic pressures are decreased. During ECMO, the goal is often to reduce the excess fluid that has accumulated in the extracellular space as a result of sepsis, inflammation, or cardiac failure. Fluid restriction and diuretics may be effective, although many patients will require extracorporeal haemofiltration. This can often be performed on blood from the ECMO circuit.
Anticoagulation is critical, to avoid the formation of clots in the ECMO circuit, while balancing the patient's risk of bleeding. Heparin is commonly used to keep the whole-blood activated clotting time (ACT) at a designated level (usually 1.5 times normal for the ACT measurement system). Thrombocytopenia is a common problem and regular platelets transfusions may be necessary to keep the platelets account over an arbitrary limit to decrease the risk of spontaneous bleeding (.150 000 ml
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). If heparin-induced thrombotic thrombocytopenia is diagnosed, the use of alternative anticoagulant is required. It is possible to run ECMO without heparin, but this increases substantially the thrombotic risk.
Contraindications
Patients with irreversible organ damage, multiorgan failure, or those who are not candidates for transplantation will usually not benefit from ECMO support. ECMO is not generally recommended in patients who cannot be anticoagulated, but this is not an absolute contraindication.
Severe aortic regurgitation or aortic dissections are contraindications for VA-ECMO. ECMO therapy is continuously evolving and it is preferable to involve an ECMO specialist in discussing indications and contraindications in each instance.
Complications
Haemorrhage and infection are the two main complications related to ECMO. Most patients require continuous anticoagulation and more than 50% of them will suffer at least one haemorrhagic complication. Half of these relate to the cannulation site and it is hoped that the development of new cannulae will reduce this risk. Arterial cannulation is related to higher risk of bleeding. Haemorrhage can occur in any organ, with intracranial bleeding being the most devastating. Improvement in heparin-bounding techniques and other materials allows interruption of systemic anticoagulation, sometimes for some days. The pathogenesis of thromboembolism during ECMO is multifactorial (i.e. blood activation after contact with foreign surfaces, blood stasis in the cardiac chambers and the systemic veins, and disseminated intravascular coagulation). Thrombus in the circuit can affect the function of the pump or the oxygenator. In VA-ECMO, it can lead to stroke or leg ischaemia. Interruption of blood flow distally to a femoral arterial cannula is a major issue that can be prevented by the insertion of a small cannula distally to the main cannula that allows part of the flow to be directed to the leg. ECMO management includes close coagulation monitoring, ensuring the best possible balance in coagulation homeostasis.
Infective complications can be related to the indwelling lines, access sites, or primary pathology. Strict aseptic handling of lines is required.
ECMO circuit failure or breakage may lead to catastrophic failure, but this is unusual as long as all components are secure. Bedside staffs are trained to check the circuit integrity regularly to prevent problems and to react promptly in the case of acute failure. Cannula displacement or malposition is a major issue as this affects blood flow and ECMO efficiency.
Where should ECMO be provided?
A multidisciplinary team approach is essential in the proper establishment of an ECMO programme. Access to specialized cardiothoracic and vascular surgical services is mandatory. Institutional criteria for ECMO management, including indications and contraindications, should be in place and a critical mass of trained staff is required. Conventional transportation of severely hypoxaemic patients in need of ECMO support may be associated with cerebral hypoxia and haemodynamic instability leading to a fatal outcome. The use of ECMO for transfer may minimize those risks, and there are a number of such uses, successful and safe. 10 Extracorporeal membrane oxygenation in adults
Conclusion
ECMO can be used in adult patients with ARDS or cardiogenic shock who failed to respond to conventional therapy. Although the evidence in favour of ECMO for ARDS treatment is not strong enough to make a general recommendation, it should be considered when other therapies fail.
The expertise of ECMO teams is improving, leading to better outcomes. Further trials are necessary to clarify the actual role of ECMO before expanding its indications.
